Want to see HK:2160 full AI Analyst Report?
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$1.04 - HK$8.46
Previous CloseN/A
Volume546.00K
Average Volume (3M)8.07M
Market Cap
HK$1.74B
Enterprise ValueHK$336.40M
Total Cash (Recent Filing)HK$1.38B
Total Debt (Recent Filing)HK$258.36M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.49
Price to Sales (P/S)6.71
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)HK$300.12M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSteady 8.7% top-line growth to 399.4M in 2025 indicates durable demand and expanding commercial traction in core products. In medtech, consistent revenue growth supports scale economics, broader hospital adoption, and a stronger base to eventually leverage fixed costs into profitability.
Healthy Gross MarginsA ~55% gross margin provides structural cushion for product gross profitability and pricing flexibility. High product-level margins allow the company to absorb distribution and R&D investment, supporting sustainable operating leverage if SG&A and R&D are controlled over the medium term.
Improving Cash Burn TrendNotable reduction in cash burn versus 2021–2024 shows improving operational cash discipline and a smaller runway gap. Even though cash flow remains negative, the trend reduces near-term refinancing needs and supports a more manageable path to operational self-sufficiency.
Bears Say
Sharp Rise In LeverageA large step-up in debt to ~1.62B and debt/equity near 6.3x materially heightens refinancing, covenant and interest-rate exposure. For a still-loss-making medtech company, elevated leverage meaningfully reduces financial flexibility and raises the probability that future capital raises will be dilutive or costly.
Sustained Net LossesDeep negative net margin (~-33%) and recurring operating losses indicate the business has yet to convert revenue scale into sustainable profitability. Persistent losses strain retained earnings, limit reinvestment capacity, and increase dependence on external financing to fund operations and growth.
Negative Free Cash FlowMeaningfully negative free cash flow (~-38.3M) alongside slightly negative operating cash flow signals the company cannot self-fund capital needs. Combined with higher leverage, persistent FCF deficits raise liquidity risk and constrain the ability to invest in R&D, commercialization, or strategic initiatives.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$1.04 and its highest was HK$8.46 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$1.74B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Sep 02, 2026 which is in 59 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
Currently, no data Available
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---